378 related articles for article (PubMed ID: 16570046)
1. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
6. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
7. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.
Lin CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2009 Jun; 42(3):227-33. PubMed ID: 19812856
[TBL] [Abstract][Full Text] [Related]
10. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.
Nasti G; Martellotta F; Berretta M; Mena M; Fasan M; Di Perri G; Talamini R; Pagano G; Montroni M; Cinelli R; Vaccher E; D'Arminio Monforte A; Tirelli U; ;
Cancer; 2003 Dec; 98(11):2440-6. PubMed ID: 14635079
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
Grabar S; Abraham B; Mahamat A; Del Giudice P; Rosenthal E; Costagliola D
J Clin Oncol; 2006 Jul; 24(21):3408-14. PubMed ID: 16849755
[TBL] [Abstract][Full Text] [Related]
13. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
14. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
15. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M; Weir J; Francis N; Newsom-Davis T; Powles S; Crook T; Boffito M; Gazzard B; Nelson M
AIDS; 2009 Aug; 23(13):1701-6. PubMed ID: 19550283
[TBL] [Abstract][Full Text] [Related]
16. Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Ahilasamy N
Int J STD AIDS; 2008 Nov; 19(11):786-8. PubMed ID: 18931277
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
18. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
Carleo MA; Di Martino F; Del Giudice A; Gargiulo M; Parrella G; Rosario P; Sangiovanni V; Viglietti R; Esposito V; Chirianni A
In Vivo; 2015; 29(1):133-6. PubMed ID: 25600542
[TBL] [Abstract][Full Text] [Related]
19. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
